stock ticker hero image

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
February 23, 2026 2:06 pm ET
Delayed at least 20 minutes

View stock information

Latest news, events, & financials

View all

  4Q25 MSD Earnings Announcement

  4Q25 MSD Other Financial Disclosures

  4Q25 Other Financial Disclosures (Excel)

  4Q25 Prepared Remarks

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline
Phase II programs
50+

Phase III programs
30+

Under review
5+

illustration of leadership speaking panel

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership
Split image showing a gloved hand holding a petri dish with greenish-blue microbial colonies on the left, and an artistic Earth covered in green foliage and blue oceans on the right

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

Download our Sustainability financing documents

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories
illustration of people and building blocks
Innovation

Our Q2 2025 financial results

MSD’s Q2 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q2 worldwide sales of $15.8 billion.​ “Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting […]

Read more
illustration of a helix with scientists
Innovation

Our Q1 2025 financial results

MSD’s Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion.​ ​”Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman and chief […]

Read more
Q4 2024_Earnings_ArticleImage
Innovation

Our Q4 and full-year 2024 financial results

MSD’s Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. ​ ​“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, […]

Read more
Contact us banner image
For questions, please contact our team.

Contact investor relations

Phone icon +1 (732) 594-1468
Email icon Email our team